Haloperidol vs. Risperidone in the Treatment of Aggression in Psychotic Inmates

This study has been terminated.

First Received: September 12, 2005 Last Updated: October 12, 2006 History of Changes

Sponsors and Collaborators:	University of Connecticut Janssen Pharmaceutica N.V., Belgium
Information provided by:	University of Connecticut
ClinicalTrials.gov Identifier:	NCT00203775

Purpose

This study examines the efficacy of haldol versus risperdal in the treatment of aggression in psychotic prison inmates. It is hypothsized that risperdal will be more effective in decreasing aggression than haldol.

Condition	Intervention
Psychosis Aggression	Drug: risperidone

MedlinePlus related topics: Psychotic Disorders

Drug Information available for: Haloperidol Haloperidol decanoate Haloperidol lactate Risperidone

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Official Title:	Efficacy of Risperidone Versus Haloperidol in the Treatment of Aggression and Hostility in Psychotic Inmates

Further study details as provided by University of Connecticut:

Study Start Date:	July 2002
Estimated Study Completion Date:	April 2004

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:age 18 or over, psychotic disorder diagnosed on SCID, inmate at correctional facility for at least 2 weeks -

Exclusion Criteria: active withdrawal from substances of abuse, non-psychotic individuals, pregnant women, people unable to give informed consent, patients on mood stabilizers

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00203775

Locations

United States, Connecticut
University of connecticut health center
farmington, Connecticut, United States, 06030

Sponsors and Collaborators

University of Connecticut

Janssen Pharmaceutica N.V., Belgium

Investigators

Principal Investigator:

catherine f lewis, md

University of Connecticut

More Information

No publications provided

Study ID Numbers:	RIS-USA-269, IRB Project Number 01-250, RIS-USA-T255
Study First Received:	September 12, 2005
Last Updated:	October 12, 2006
ClinicalTrials.gov Identifier:	NCT00203775 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Neurotransmitter Agents
Tranquilizing Agents
Psychotropic Drugs
Risperidone
Central Nervous System Depressants
Antiemetics
Antipsychotic Agents
Serotonin
Behavioral Symptoms
Schizophrenia

Haloperidol
Haloperidol decanoate
Dopamine
Mental Disorders
Dopamine Agents
Psychotic Disorders
Peripheral Nervous System Agents
Aggression
Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Physiological Effects of Drugs
Psychotropic Drugs
Antiemetics
Haloperidol
Serotonin Antagonists
Mental Disorders
Therapeutic Uses
Psychotic Disorders
Aggression
Schizophrenia and Disorders with Psychotic Features

Tranquilizing Agents
Risperidone
Gastrointestinal Agents
Central Nervous System Depressants
Dopamine Antagonists
Antipsychotic Agents
Pharmacologic Actions
Behavioral Symptoms
Serotonin Agents
Autonomic Agents
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on May 07, 2009